McKesson Future Growth

Future criteria checks 2/6

McKesson is forecast to grow earnings and revenue by 9.6% and 8.1% per annum respectively. EPS is expected to grow by 13.3% per annum. Return on equity is forecast to be 247% in 3 years.

Key information

9.6%

Earnings growth rate

13.3%

EPS growth rate

Healthcare earnings growth19.3%
Revenue growth rate8.1%
Future return on equity247.0%
Analyst coverage

Good

Last updated14 Oct 2024

Recent future growth updates

No updates

Recent updates

McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff

Oct 09

McKesson: The Correction Is Not Over

Sep 10

McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing

Aug 22
McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

Jul 04

With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

May 09
With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

Mar 14
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

McKesson: GLP-1 Contributed More Than 1/3 Of Growth

Feb 19

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Feb 16
McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

Jan 29
Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

McKesson: Why The Company Is Too Richly Valued

Jan 19

If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

Nov 20
If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase

Nov 08

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

Oct 30
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

McKesson: Still Trading For A Huge Discount

Sep 06

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Aug 21
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

Jul 27
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation

Jun 28

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

May 23
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Apr 17
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

Feb 22
Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth

Feb 08

McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M

Feb 01

McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

Jan 12
McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

5 Reasons Why I Am Considering Adding McKesson To My Portfolio

Dec 27

McKesson Corporation: Still Trading Below Intrinsic Value

Dec 13

Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus

Oct 08

McKesson extends distribution partnership with CVS Health

Sep 29

An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

Sep 19
An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

Earnings and Revenue Growth Forecasts

NYSE:MCK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027411,1764,3555,6906,44411
3/31/2026382,5814,0174,8695,87315
3/31/2025351,7763,7374,9985,73715
6/30/2024313,7512,9593,2563,986N/A
3/31/2024308,9513,0023,6274,314N/A
12/31/2023301,5062,9982,8923,492N/A
9/30/2023291,0983,4874,3064,906N/A
6/30/2023284,0403,7554,4665,048N/A
3/31/2023276,7113,5634,6015,159N/A
12/31/2022273,9033,1464,1904,721N/A
9/30/2022272,0272,0613,9524,430N/A
6/30/2022268,4461,3964,6395,115N/A
3/31/2022263,9661,1193,8994,434N/A
12/31/2021257,0061,4154,3234,917N/A
9/30/2021250,991-4,8044,0984,753N/A
6/30/2021245,223-4,4943,2993,982N/A
3/31/2021238,228-4,5383,9014,542N/A
12/31/2020237,621-4,1895,2315,826N/A
9/30/2020234,1942,2283,9054,492N/A
6/30/2020231,0029222,8513,363N/A
3/31/2020231,0519063,8684,374N/A
12/31/2019224,945-9053,1253,615N/A
9/30/2019221,981-6263,0663,559N/A
6/30/2019217,4406014,5235,046N/A
3/31/2019214,319333,4794,036N/A
12/31/2018213,518-3192,5723,165N/A
9/30/2018210,9271132,7513,324N/A
6/30/2018209,913-3841,9362,543N/A
3/31/2018208,35762N/A4,345N/A
12/31/2017205,4424,805N/A2,756N/A
9/30/2017201,9554,539N/A3,155N/A
6/30/2017199,8514,846N/A3,626N/A
3/31/2017198,5335,194N/A4,744N/A
12/31/2016196,4982,051N/A6,415N/A
9/30/2016194,2672,044N/A5,349N/A
6/30/2016193,0712,359N/A5,077N/A
3/31/2016190,8842,290N/A3,672N/A
12/31/2015189,1312,237N/A2,449N/A
9/30/2015187,7162,090N/A4,198N/A
6/30/2015183,1151,950N/A3,384N/A
3/31/2015179,0451,775N/A3,112N/A
12/31/2014171,9521,780N/A3,893N/A
9/30/2014159,8041,462N/A2,488N/A
6/30/2014148,6291,402N/A2,602N/A
3/31/2014137,3921,419N/A3,136N/A
12/31/2013130,0761,278N/A2,679N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MCK's forecast earnings growth (9.6% per year) is above the savings rate (2.5%).

Earnings vs Market: MCK's earnings (9.6% per year) are forecast to grow slower than the US market (15.9% per year).

High Growth Earnings: MCK's earnings are forecast to grow, but not significantly.

Revenue vs Market: MCK's revenue (8.1% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: MCK's revenue (8.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MCK's Return on Equity is forecast to be very high in 3 years time (247%).


Discover growth companies